MCP: Cardiovascular Part 1-HTN Flashcards
1
Q
HTN Definition
A
- Persistently elevated arterial BP
- Patients actively taking antihypertensive medications are considered to have HTN (regardless of BP)
2
Q
HTN Prevalence
A
- 1 in 3 Americans
- Often has no symptoms
- “Silent Killer”
- Some symptomsm might include: dizzy spells, dull HA, nosebleeds
3
Q
Impact of HTN
A
- BP correlates directly to risk of cardiovascular morbidity and mortality
- Leads to damage of blood vessels and target organs
- Heart
- Heart disease
- Coronary artery disease
- CV events
- MI
- Chest Pain (Angina)
- Heart Failure
- Heart disease
- Brain
- Cerebrovascular Events
- Stroke
- Cerebrovascular Events
- Kidney
- Kidney Disease
- Heart
4
Q
HTN: As a Major Risk Factor
A
- Major risk factor for heart disease
- The 1st leading cause of death for all Americans
- High BP, 3x more likely for heart disease
- Major risk factor for stroke
- The 4th leading cause of death for all Americans
- High BP, 4x more likely for stroke
5
Q
Lifestyle Modifications
A
- Increased physical activity
- Weight loss
- DASH diet
- Reduced alcohol intake
- Smoking cessation
6
Q
DASH Diet
A
- Reduce risk of HTN and reduce blood pressure for those with HTN
- Limit sodium consumption to 2300mg/day
- Ideally 1500mg/day
- Diet rich in fruits and vegetables
- Increase in minerals such as potasium, calcium and magnesium
- Increase in fiber
- Low in saturated fats, choleseterol, and total fat
7
Q
Modification and BP Reducation
A
- Weight Loss
- 5-20 mmHg
- DASH
- 8-14 mmHg
- Limit Sodium
- 2-8 mmHg
- Physical Activity
- 4-9 mmHg
- Moderation of Alcohol Consumption
- 2-4 mmHg
8
Q
JNC-7 BP Diagnostic Ranges
A
- Normal: 120/80
- Pre-HTN: 120-139/80-89
- HTN Stage 1: 140-159/90-99
- HTN Stage 2: >160/>100
- HTN Crisis: >180/>110
- Goal BP with comorbidities: <130/80
- DM, MI, CKD
9
Q
JNC-8 New Blood Pressure Goals
A
- 18-59 yo with no commorbidities
- 140/90
- 60 yo with no commorbodiities
- 150/90
- 18 to <70 yo with CKD or DM
- 140/90
10
Q
JNC7/JNC8 Difference in a Nutshell
A
- Definition of HTN and pre-HTN were not specifically addressed in JNC8
- Thresholds for BP treament were adopted that were consistent with JNC-7 definition
- JNC8 advice higher BP goals in certain populations and decreased use of several antihypertensives
- follow a different classification system based on age and commorbidities
- Promote safer use of ACE inhibitors and ARBs, no longer promotes beta blockers and aldosterone agonists as a first and second line treatment.
11
Q
Screening vs. Diagnosis
A
- Elevated BP results in screening do not constitute diagnosis
- Proper HTN diagnosis:
- Multiple high BP readings on different days at office visits
- Some consideration for diagnosis of HTN based on at home BP monitoring
- 12-14 reading, both morning and evening reading, over 1 week
- Some consideration for diagnosis of HTN based on at home BP monitoring
- Multiple high BP readings on different days at office visits
- Multiple other physical exam procedures to check cardiac function and HTN complications
12
Q
BP Management and Monitoring
A
- HC Provider Monitoring:
- Monthly BP checks until reach goal
- More frequent visits if stage 2 HTN
- Monthly BP checks until reach goal
- Self-Monitoring:
- Various studies have shown that home monitoring can increase medication concordance and BP control
- Management:
- Lifestyle recommendations recommended for those with pre-HTN and HTN (encouraged for everyone)
- JNC-7
- Stage 1 HTN: At least one anti-htn med
- Stage 2 HTN: 2 anti-HTN medications recommended
13
Q
General Counseling Points
A
- Always encourage a healthy diet and lifestyle
- Time to Effect:
- May take 2-3 weeks to see sustained effects in blood pressure, though they may feel side effects in the first couple of days
- Concordance:
14
Q
Medications Used for Hypertension
A
- Thiazide diuretics
- Angiotensin Converting Enzyme Inhibitors (ACE I)
- Angiotensin II Receptor Blockers (ARBs)
- Calcium Channel Blockers (CCB)
- Beta Blockers
15
Q
Thiazide Diuretics: Indications, MOA
A
- Indications:
- HTN
- Mild edema
- MOA:
- Inhibits Na and Cl reabsorption from teh distal tubule nephron –> increased urinary excretion of water
- Water follows salt
- Reduces blood volume in order to reduce blood pressure
16
Q
Thiazide Diuretics: Side Effects
A
- Polyuria
- Orthostatic hypotension
- Hypokalemia
- Photosensitivity
- Hyperglycemia and dyslipidemia (more common at higher doses)
17
Q
Thiazide Diuretics: Counseling Points
A
- Dose in morning to avoid disturbing sleep
- Rare: Sulfa allergies
18
Q
Thiazide Diuretics: Monitoring
A
- Blood pressure
- Potassium
- Blood Glucose (those with DM)
- Dyslipidemia (standard monitoring, but may watch more carefully)
19
Q
Thiazide Diuretics: Agents
A
- Hydrochlorothiazide (Microzide, HCTZ)
- High doses are associated with increased adverse effects without added clinical benefits
- Chlorthalidone (Hygroton)
20
Q
Angiotensin Converting Enzymes (ACE) Inhibitors: Indications and MOA
A
- Indications:
- Hypertension
- Heart Failure
- Prevention/Treatment of Diabetic Nephropathy
- MOA
- Suppresses renin-angiotension-aldosterone system by blocking the conversion of angiotensin I to angiotensin II (potent vasocontrictor)
21
Q
ACE Inhibitors: Side Effects
A
- Dry cough
- Hyperkalemia
- Caution with potassium suplements of potassium sparing diuretics
- Avoid combining with ARB
22
Q
ACE Inhibitors: Notes and Monitoring
A
- Notes:
- Contraindcated in pregnancy (Category X)
- Acute renal failure (rare)
- Monitoring:
- Blood pressure
- Renal function (SCr), potassium
23
Q
Benazepril
A
- ACE
- Lotensin
24
Q
Enalapril
A
- ACE
- Vasotec
25
Lisinopril
* Prinivil, Zestril
* ACE
26
Ramipril
* ACE
* Altace
27
Angiotensin II Receptor Blockers (ARBs): Indications, MOA
* Indications:
* HTN
* Heart failure (for those not tolerant to ACEI)
* Prevention/treatment of diabetic nephropathy
* MOA:
* Suppresses renin-angiotensin-aldosterone system by blocking the angiotensin II receptor--\>inhibits vascontrictive effects
28
ARBs: Side Effects
* Generally well tolerated
* Hyperkalemia
* Orthostatic hypotension
* Angioedema
29
ARBs: Notes and Monitoring
* Notes:
* Minimal effect on bradykinin--\>alternative for patients who experience ocuge with ACEI
* Avoid in pregnancy (Cat D)
* Monitoring:
* Blood Pressure
* Renal function (SCr), potassium
30
ACE Inhibitors: Drugs
* Benazepril
* Enalapril
* Lisinopril
* Ramipril
31
ARB: Drugs
* Candesartan
* Irbesartan
* Losartan
* Valsartan
32
Candesartan
* ARB
* Atacand
33
Irbesartan
* Avapro
* ARB
34
Losartan
* Cozaar
* ARB
35
Valsartan
* ARB
* Diovan
36
Calcium Channel Blockers (Dihydropyridines): Indications and MOA
* Indications:
* HTN
* Chronic stable angina
* MOA
* Inhibits calcium movement across membranes, relaxing coronary vascular smooth muscle--\>vasodialation and increasing myocardial oxygen supply
37
CCB-Dihydropyridines: Side Effects
* Flushing, dizziness, lightheadness
* HA
* Peripheral edema
38
CCB-Dihydropyridines: Notes and Monitoring
* Notes:
* Nifedipine: Avoid immediate release formulation for HTN
* Monitoring:
* Blood pressure
* Swelling of extremities
39
CCB-Dihydropyridines: Drugs
* Amlodipine
* Nifedipine
40
Amlodipine
* CCB
* Norvasc
41
Nifedipine
* CCB
* Procardia XL
* IR has increased risk of morbididty
42
CCB (Non-dihydropyridines): Indications and MOA
* Indications
* HTN
* Heart rate control (AFib)
* Angina
* MOA:
* Similar to dihydropyridines except with negative ionotropic effects
* Depress impulse formation and conduction velocity in the AV node
* Reduces ability of the heart to contract
43
CCBs-Non-Dihydropyridines: Side Effect
* Diltiazem: bradycardia, hypotension, peripheral edema, nausea, gingival hyperplasia
* Verapamil: same as diltiazem, constipation
44
CCBs-Non-Dihydropyridines (Counseling Points)
* Diltiazem: Take on an empty stomach
* Verapamil: Sustained release must be taken with food
* Lots of drug interactions
* Avoid in patients with heart failure or acute MI
45
CCB-Nondihydropyridines: Monitoring
* Blood Pressure
* Heart Rate
* ECG: Conditions being treated also involved
* e.g. arrhythmia
* Liver Function Tests
46
CCB (Non-Dihydropyridines): Drugs
* Verapamil
* Diltiazem
47
Verapamil
* Calan
* CCB Non-dihydropyridines
48
Diltiazem
* Cardizem
* CCB: nondihydropyridines
49
Beta Blockers: Indications and MOA
* Indications:
* HTN (not first line)
* Angina
* Arrythmia
* MI
* Non-cardiovascular conditions (glaucoma, stage fright (propranolol)
* MOA:
* Block beta-adrenergic receptors--\>decrease heart rate, decrease BP, decrease myocardial oxygen demand and myocardial contraction
50
BB: Side Effects
* Bradycardia
* Fatigue
* Dizziness
* Propranolol (most), Atenolol (least)
* Acute Heart Failure
* Bronchoconstriction (non-selective or selvetice at high doses)
51
BB: Couseling points, notes, monitroing
* Counseling Points
* Avoid abrupt discontinuation--\>withdrawl syndrome
* Increase BP, tachycardia, nervousness/sweating, and MI
* Notes
* Caution in patients with DM and asthma
* Monitoring
* BP
* Heart Rate
* ECG
52
BB: Drugs
* Atenolol
* Carvedilol
* Metoprolol
* Propranolol
53
Atenolol
* Tenormin
* Cardio-selective for B1
* BB
54
Carvedilol
* Coreg
* IR and ER
* BB
55
Metoprolol
* Tartrate (Lopressor)
* Succinate (Toprol XL)
* BB
* Cardio Selective for B1
56
Propranolol
* Inderal
* BB